Evaluate

January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.

July 06, 2016

Second-quarter biotech IPOs stagnate as outlook worsens

April 20, 2016

Scuttled IPOs cast pall on struggling biotech sector